Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 302

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 302
---
%3F,t%20know%20they
%20have%20it. 148

Basis of revenue assumptions Development of the revenue estimates for Lumee Oxygen and Lumee Glucose relied on calculations of the total addressable market available to potential penetration by both products. In the case of Lumee Glucose, revenue includes both sales of Lumee Glucose in its personal use and professional -useapplications. Profusa calculated the total addressable market by defining relevant active market segments in both the United States and European Union for both Lumee Oxygen and Lumee Glucose. Market segments for Lumee Glucose included Type 1 and Type 2 diabetics, Type 2 diabetics not on insulin, prediabetic, and the emerging health and wellness segment. The market segments used for Lumee Oxygen were the critical limb ischemia (CLI) and peripheral arterial disease (PAD) segment. The table below shows the total addressable patient population across the market segments discussed above for each of Lumee Glucose and Lumee Oxygen in each of the United States and the Europe Union. The numbers below are presented in millions.

| Product Line  |     | Region |     |  2026 |     |  2027 |     |  2028 |     |  2029 |     |  2030 |
| Lumee Glucose |     | US     |     | 35.85 |     | 37.53 |     | 39.34 |     | 41.31 |     | 43.49 |
| Lumee Glucose |     | EUR    |     | 38.31 |     | 40.08 |     | 41.99 |     | 44.08 |     | 46.37 |
| Lumee Oxygen  |     | US     |     | 31.94 |     | 32.26 |     | 32.58 |     | 32.91 |     | 33.24 |
| Lumee Oxygen  |     | EUR    |     | 40.70 |     | 41.63 |     | 42.57 |     | 43.73 |     | 44.71 |

Management then applied estimates of Lumee Oxygen and Lumee Glucose penetration rates in each of the market segments. The average estimated penetration rate for Lumee Glucose across all market segments in Europe ranged from .03% in 2026 to an average .88%